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Abstract
Increasing interest surrounds potential neuroprotective or neurotrophic actions of antidepressants. While
growing evidence points to important early clinical and neuropsychological eﬀects of antidepressants,
the time-course of any eﬀect on neuronal integrity is unclear. This study used magnetic resonance
spectroscopy to assess eﬀects of short-term treatment with escitalopram on N-acetyl-aspartate (NAA), a
marker of neuronal integrity. Thirty-nine participants with major depression were randomly assigned
to receive either 10 mg escitalopram or placebo daily in a double-blind, parallel group design. On the
seventh day of treatment, PRESS data were obtained from a 30r30r20 mm voxel placed in medial frontal
cortex. Age and gender-matched healthy controls who received no treatment were also scanned. Levels
of NAA were signiﬁcantly higher in patients treated with escitalopram than in either placebo-treated
patients (p<0.01) or healthy controls (p<0.01). Our ﬁndings are consistent with the proposition that
antidepressant treatment in depressed patients can produce early changes in neuronal integrity.
Received 30 November 2011 ; Reviewed 4 January 2012 ; Revised 23 February 2012 ; Accepted 27 February 2012 ;
First published online 26 March 2012
Key words : Antidepressant, depression, magnetic resonance spectroscopy, N-acetyl-aspartate.
Introduction
There is increasing interest in the potential neuropro-
tective or neurotrophic action of antidepressant treat-
ments (Schmidt & Duman, 2007). N-acetyl-aspartate
(NAA) is a marker of neuronal integrity, synthesized
within neuronal mitochondria (Moﬀett et al. 2007), that
can readily be measured using the safe, non-invasive
technique of magnetic resonance spectroscopy (MRS).
If antidepressant treatment acts via a neurotrophic
mechanism, increased levels of NAA might be ob-
served. Indeed, in animal studies, it has been found
that antidepressant treatment can prevent stress-
induced decreases in NAA (van der Hart et al. 2002). In
addition, some clinical reports have noted increases in
NAA in frontal cortex with antidepressant treatment
over periods of several weeks (Gonul et al. 2006;
Huang et al. 2010 ; Jang et al. 2006) although there are
also some negative ﬁndings (Henigsberg et al. 2011 ;
Kaymak et al. 2009).
Clinical trial evidence shows that antidepressants
such as selective serotonin reuptake inhibitors (SSRIs)
have an early onset of clinical eﬀects detectable with
standard rating scales within 1 wk (Taylor et al. 2006).
Consistent with this, early eﬀects on behavioural and
neural aspects of emotional processing are observed
after even a few days administration of anti-
depressants (Harmer et al. 2004). If neurotrophic ef-
fects are mechanistically important in therapeutic
response, they should also be evident after short-term
treatment of depression with an SSRI. Escitalopram is
a clinically eﬀective antidepressant and the most
selective of the SSRIs for the serotonin transporter. We
hypothesized that 7 d treatment with escitalopram
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would lead to an increase in cortical NAA levels.
Accordingly, the aim of the present study was to
compare the neurochemistry of the medial prefrontal
cortex in two groups of depressed patients, one un-
medicated and one who had received short-term
treatment with the SSRI, escitalopram.
Method
Design
Drug-free depressed patients were randomly assigned
to receive 10 mg escitalopram or placebo daily for 7 d
in a double-blind, parallel group design. Both groups
were then scanned on the seventh day of treatment.
The escitalopram dose was chosen as this is the manu-
facturer’s recommended treatment dose for major de-
pressive episodes. The elimination half-life after
multiple dosing is about 30 h. Ratings of mental state
were obtained using the 17-item Hamilton Depression
Rating Scale (HAMD-17; Hamilton, 1967), Beck
Depression Inventory (BDI ; Beck et al. 1961) and the
State-Trait Anxiety Inventory (Spielberger et al. 1970).
An age and gender-matched group of healthy controls
were scanned on a single occasion and received no
treatment.
Participants
Thirty-nine participants with major depression and
27 healthy controls completed the MRS protocol.
Controls were recruited through university volunteer
lists and advertising in local newspapers. Depressed
patients were recruited from a number of sources, in-
cluding newspaper advertisements as well as referral
from other clinicians. All participants were assessed
for the presence of current and past psychiatric
disorder with the Structured Clinical Interview for
DSM-IV (First et al. 2002). The depressed patients met
criteria for a primary diagnosis of major depressive
disorder. Exclusion criteria for the study were as fol-
lows. For depressed patients : suﬀering from psychosis
or substance dependence as deﬁned by DSM-IV; being
at clinically signiﬁcant risk of suicidal behaviour ;
having contraindications to escitalopram treatment ; or
being treated with psychotropic medication <3 wk
before the study (5 wk in the case of ﬂuoxetine). For
healthy volunteers : current or past history of Axis I
disorder as deﬁned by DSM-IV. For both groups:
major somatic or neurological disorders ; pregnancy or
breast-feeding ; contraindications to magnetic reson-
ance imaging or concurrent medication, which could
alter emotional processing. No minimum HAMD-17
score was required. The study was approved by the
Oxford Research Ethics Committee and all partici-
pants gave written informed consent. Participants
were reimbursed for their time and any other ex-
penses.
MRS methodology
Scanning was performed on a 3T Siemens Trio
(Erlangen, Germany) system with a head gradient coil
(Magnex Scientiﬁc, Oxford) and a 12 channel head-
only receive array RF coil. Data were acquired from a
30r30r20 mm voxel placed in the medial prefrontal
cortex anterior to the genu of the corpus callosum
(Supplementary Fig. S1). The voxel was positioned
manually by reference to an axial T1-weighted
gradient-echo image.
PRESS data (Bottomley, 1987) with water sup-
pression were acquired (TE 30 ms, TR 3 s, 64 aver-
ages). PRESS data were analysed with LCModel
(Provencher, 1993) using a set of simulated metab-
olite basis spectra. Concentrations relative to creatine
(Cr) were obtained for NAA, the total of NAA
and N-acetylaspartylglutamic acid (NAA+NAAG),
choline, inositol and total combined glutamate and
glutamine (Glx). Concentration estimates with
Cramer–Rao lower bounds (CRLB) >20% were re-
jected as unreliable. In a subset of participants
(29 patients, 15 controls) PRESS-J data (Hurd et al.
2004) were also acquired (TE 35–185 ms, 10 ms in-
crements, total 128 acquisitions, TR 3 s). Estimates
of glutamate relative to Cr were obtained using
AMARES (Vanhamme et al. 1997). Estimates with
damping factor >55 were excluded. T1-weighted
structural images of whole brain were acquired with
1 mm3 voxel resolution. FSL FAST was employed to
segment the structural brain images into grey matter,
white matter and cerebrospinal ﬂuid, to allow esti-
mation of voxel composition. Group diﬀerences were
tested using the general linear model in PASW
Statistics v18 (SPSS Inc., USA) employing analysis of
variance or analysis of covariance as appropriate
with post-hoc t test. Results were tested for sensitivity
to the inclusion or exclusion or age, gender and voxel
grey matter content as covariates. A conventional
two-tailed statistical signiﬁcance threshold of p=0.05
was applied throughout.
Results
The three groups were demographically similar
(Table 1). After 1 wk of treatment, there was no sig-
niﬁcant diﬀerence in rating scale scores between
those patients receiving placebo and those receiving
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escitalopram (HAMD-17 p=0.59 ; BDI p=0.93 ; state
anxiety p=0.49 ; Table 1).
A signiﬁcant eﬀect of group was seen on
NAA+NAAG/Cr (placebo 1.07¡0.16, escitalopram
1.18¡0.18, healthy 1.06¡0.16, p=0.03) and NAA/
Cr (placebo 0.99¡0.16, escitalopram 1.13¡0.19,
healthy 0.96¡0.18, p<0.01 ; Fig. 1) but not on other
metabolites measured (p>0.35 in all cases). Levels
of NAA/Cr were higher in patients randomized to
7 d treatment with escitalopram than in those re-
ceiving placebo (p<0.01) or in healthy controls
(p<0.01). The same eﬀect was seen with the more
conservative NAA+NAAG/Cr measure (p<0.05
both cases). There was no diﬀerence between
NAA/Cr or NAA+NAAG/Cr levels between the
placebo group and healthy controls (p>0.7 both
cases).
A small but statistically signiﬁcant inverse eﬀect of
age on NAA/Cr was observed (r=x0.26, p=0.03)
across the entire group. No agergroup interaction on
NAA/Cr was observed and the group eﬀect remained
with age as a covariate (p<0.01). No eﬀect was seen of
age on NAA+NAAG/Cr (p=0.19). No group eﬀect
on Glx/Cr was observed, but there was an inverse
correlation between baseline depression rating scale
score and Glx/Cr in the depressed group (r=x0.39,
p=0.015).
Metabolite estimates were obtained with a high de-
gree of conﬁdence. Mean CRLB for NAA+NAAG/Cr
estimates was 3.65% and for NAA/Cr estimates was
4.94% (see Supplementary Table S1).
Discussion
The main ﬁnding of this study was that after 7 d
treatment of depression with escitalopram, elevated
levels of NAA are observed in the medial frontal cor-
tex. As NAA is one of the major peaks on proton MRS
spectrum (Supplementary Fig. S1), quantitation can be
Table 1. Participant characteristics
Placebo (n=19) Escitalopram (n=20) Healthy (n=27)
Age, yr 32.4 (12.0)
range 18–56
30.6 (8.5)
range 19–51
31.4 (11.1)
range 19–58
Gender 9 male/10 female 8 male/12 female 9 male/18 female
HAMD-17 : baseline 23.2 (4.6) 24.2 (5.7) 0.5 (0.7)
7 d 20.4 (4.2) 19.3 (7.9) –
BDI : baseline 31.5 (9.7) 30.8 (9.6) 1.1 (1.3)
7 d 25.1 (9.0) 24.8 (12.0) –
STAI state : baseline 49.2 (17.7) 47.5 (23.6) 27 (5.3)
7 d 47.3 (10.5) 49.9 (11.8) –
Voxel grey-matter
percentage
43 (5) 43 (4) 42 (5)
Voxel CSF
percentage
21 (5) 22 (3) 21 (4)
HAMD-17, Hamilton Depression Rating Scale ; BDI, Beck Depression Inventory;
STAI, State-Trait Anxiety Inventory ; CSF, cerebrospinal ﬂuid.
Values are mean (S.D.).
No signiﬁcant diﬀerences between patient groups.
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Fig. 1. Concentrations of magnetic resonance spectroscopy
measures. Concentrations of N-acetyl-aspartate (NAA)+
N-acetylaspartylglutamic acid (NAAG), NAA alone, total
combined glutamate and glutamine (Glx), inositol, choline
and glutamate are shown for depressed patients receiving
placebo (n=19, ), depressed patients receiving escitalopram
(n=20,&) and healthy controls (n=27,%). Mean with S.E.M.
* p<0.05 post-hoc t test ; # glutamate data from subset
(placebo n=16, escitalopram n=13, control n=15).
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achieved with high accuracy, lending conﬁdence to
this result.
An increase in NAA in similar brain regions
has been reported after longer-term response to a
variety of antidepressants for major depression
(Gonul et al. 2006) and after 12 wk treatment of
obsessive–compulsive disorder with citalopram (Jang
et al. 2006). However, not all have reported similar
ﬁndings (Henigsberg et al. 2011; Kaymak et al. 2009),
suggesting that patient heterogeneity might be a
factor. For example, a signiﬁcant proportion of our
patients were drug naive and none was treatment-
resistant. It should also be noted that we did not
observe any eﬀect on NAA in previous studies of
citalopram in healthy volunteers (Taylor et al. 2008,
2010), which suggests there may be an interaction of
treatment and underlying disease factors.
No diﬀerence in NAA levels was seen here between
placebo-treated depressed patients and healthy con-
trols. A lack of eﬀect of depression itself on observed
NAA levels is consistent with many prior studies that
have found no signiﬁcant eﬀect of depression on NAA
in this region (Yildiz-Yesiloglu & Ankerst, 2006). More
recently, some studies have found decreased NAA in
medial prefrontal cortex in particular populations.
One study found decreased NAA+NAAG in chronic
and relapsing–remitting subgroups, but not in the
early phases of the illness (Portella et al. 2011).
Decreased NAA was also found in a group of patients
prior to electroconvulsive therapy treatment (Merkl
et al. 2010). Thus, as with the eﬀects of treatment on
NAA, it is possible that a diﬀerence could have been
observed if the patients studied had diﬀerent clinical
characteristics.
NAAG is a neuropeptide synthesized from NAA
and glutamate and also found localized within neur-
ons (Moﬀett et al. 2007). There is substantial overlap of
MRS signal from NAA and NAAG. While the total
combined signal is readily measured using MRS, er-
rors in correctly attributing components of that signal
to NAA or NAAG are a possible cause of erroneous
ﬁndings. In these data, eﬀects were observed whether
NAA or NAA+NAAG was considered, which lends
support to the eﬀect seen.
The eﬀect here was demonstrated in medial pre-
frontal cortex. Future studies could investigate a wider
range of brain structures because eﬀects on hippo-
campal and amygdala function are likely to be im-
portant in antidepressant actions (Schmidt & Duman,
2007). While one recent study of paroxetine for gen-
eralized anxiety found no eﬀect on hippocampal NAA
levels (Mathew et al. 2010), increases in hippocampal
NAA with extended SSRI treatment have now been
described in other patient populations (Duan et al.
2011; Huang et al. 2010).
This study reported concentrations relative to Cr,
which is conventional. It is possible that apparent
changes in NAA:Cr ratio could be explained by alter-
ations in Cr levels. This seems unlikely to explain
the eﬀect seen here, since no change was observed in
other metabolites, also referenced to Cr. Nevertheless,
future studies could also reference concentrations to
tissue water, to avoid this potential confound. The
major methodological limitation of our study is the
cross-sectional design. Thus, although we have a
reasonable sample size, it is possible that the diﬀer-
ence in NAA, which we detected at 7 d, is actually due
to baseline diﬀerences between the subject groups.
Clearly a further study with longitudinal design is
necessary to control for this possibility and to allow for
investigation of any link between the early neuronal
eﬀects observed here and eventual clinical response.
Within these limitations, our ﬁndings are consistent
with a neurotrophic hypothesis of antidepressant
action.
Some investigations have reported lower levels of
Glx in anterior brain regions in depressed patients
but not all studies are in agreement (Yu¨ksel & O¨ngu¨r,
2010). No group eﬀect on Glx was observed here, but
the inverse correlation between depression severity
and Glx suggests that an eﬀect might have been seen
if a more severely depressed group of patients had
been studied. However, the correlation observed
would not have survived correction for multiple
comparisons, so interpretation of the ﬁnding needs to
be cautious. We used PRESS-J to derive a measure
of glutamate separate from Glx in a subgroup of
patients but again found no diﬀerence between the
depressed patients and controls. There is evidence
from the study of Portella et al. (2011) that lowered
Glx levels may be more apparent in patients with
chronic depression, which might make such a change
less likely to be detected in our particular patient
group (see above). Better measures of glutamate in
larger patient groups will be needed to address this
issue more deﬁnitively.
The lack of eﬀect of short-term SSRI treatment
on glutamate and Glx in anterior brain regions is
consistent with our previous studies in healthy
volunteers (Taylor et al. 2010). Our ﬁndings are
consistent with the proposition that antidepressant
treatment in depressed patients can produce early
changes in neuronal integrity. Future studies should
clarify whether an early change in NAA could be
a possible early biomarker of treatment eﬀect in
depressed patients.
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